MEDF — Medfield Diagnostics AB Income Statement
0.000.00%
- SEK14.28m
- SEK11.65m
- SEK0.71m
Annual income statement for Medfield Diagnostics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.854 | 1.2 | 0.4 | 2.4 | 0.713 |
Cost of Revenue | |||||
Gross Profit | 3.79 | 5.83 | 7.15 | 8.27 | 5.46 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8.94 | 8.46 | 7.66 | 10.8 | 14.6 |
Operating Profit | -8.08 | -7.26 | -7.26 | -8.38 | -13.9 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -8.09 | -7.26 | -7.26 | -8.37 | -15 |
Net Income After Taxes | -8.09 | -7.26 | -7.26 | -8.37 | -15 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.09 | -7.26 | -7.26 | -8.37 | -15 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.09 | -7.26 | -7.26 | -8.37 | -15 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.276 | -0.22 | -0.185 | -0.22 | -0.19 |
Dividends per Share |